A 2020 update on the progress of treatment and new drug clinical trials for hepatitis B

VernacularTitle:2020年慢性乙型肝炎治疗和新药临床研究进展
Author: Jidong JIA ¹ ; Junqi NIU ; Hong YOU ; Yuanyuan KONG ; Jinlin HOU
Author Information

1. 首都医科大学附属北京友谊医院肝病中心　100050
Keywords: Hepatitis B; Antiviral therapy; Functional cure; Clinical trial
From: Chinese Journal of Hepatology 2021;29(2):97-101
CountryChina
Language:Chinese
Abstract: Long term antiviral therapy with nucleos(ti)ide analogues could suppress HBV viral load thereby prevent the progression to cirrhosis and hepatocellular carcinoma. Interferon-based therapy could result in sustained virological response in a fair proportion of patients and even HBsAg loss in a small proportion of them. Novel therapies aiming at functional cure (loss of HBsAg) are under active development. Among the categories of many, HBV core protein inhibitors are safe and could suppress the HBV DNA and HBV RNA, but only with modest effect on the level of HBsAg; silencing of HBV mRNA by siRNA or antisense oligonucleotides could produce meaningful and sustainable declining in HBsAg levels; immune modulators with different mode of action showed modest effect on the reduction of HBsAg, but with noticeable adverse event (especially transaminase flares) related to the mode of action. Novel clinical trial design on the combination or sequential use of innovative molecules will ultimately lead to the functional cure of CHB in the near future.